Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Use of human lysozyme in preparation of medicine for unhealed ulceration by wound inflammation

A technology for human lysozyme and wound infection, applied in the directions of drug combination, drug delivery, pharmaceutical formulation, etc., can solve problems such as non-healing of wounds, and achieve the effects of safe and toxic side effects, convenient use and simple preparation process.

Inactive Publication Date: 2005-02-23
张华
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Staphylococcus aureus (MRSA) infection caused by burns, scalds, and poor peripheral microcirculation in the late stage of diabetes, wound non-healing, AIDS-induced wound ulceration caused by Staphylococcus aureus (MRSA) has no cure except vancomycin, and aeruginosa Pseudomonas is basically incurable clinically

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0170] Recombinant human lysozyme is based on the preparation of 200 ml of medium, with H 3 PO 4 4-8ml, MgSO 4 1-5 grams, K 2 SO 4 2-6 grams, KOH1-3 grams, CaSO 4 2H 2 O1-3.5 grams, add distilled water to 200 milliliters, inoculate glycerin tube seeds after autoclaving, shaker rotation speed is 250 revolutions per minute, culture temperature is 20-35 ℃, cultivate 36-48 hours on constant temperature bed. After the seed tank culture is carried out, the production tank culture is carried out. Extracting and purifying the culture solution after fermentation and expression, freeze-drying the extracted and purified protein concentrate, measuring protein quantity, purity and preservation of lysozyme activity. The recombinant human lysozyme with a purity of 95% is prepared from 300U to 3 million U / mL, and the phosphate buffer is 10 to 20mM (pH6.5 to 7.5) 80%, 5 to 25% propylene glycol, and 5 / 10000 Tween 80 , mixed homogeneously at normal temperature, (in a pharmaceutical factor...

Embodiment 2

[0172] Made of recombinant human lysozyme with a purity of 85%-99%, 300U-3 million U / ml, phosphate buffer 10 (pH6.0) 80%, 20% propylene glycol, 6% sodium 2-pyrrolidone-5-carboxylate , 0.9% water-soluble azone, 3 / 10,000 Tween 80 (in a pharmaceutical factory meeting the GMP requirements, completed according to pharmaceutical regulations) drops, milk, emulsion.

Embodiment 3

[0174] Made with recombinant human lysozyme with a purity of 85%-99%, 300U-3 million U / ml / g, phosphate buffer 20mM (pH7.0) 85%, 20% propylene glycol, 1% carbo resin, and 0.3% essence (In a pharmaceutical factory that meets the requirements of GMP, it is completed according to pharmaceutical regulations) cream.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

An application of human lysozyme in preparing the medicines is the form of spray, drops, or cream for treating burn, scald and the wound infection and ulcer caused by diabetes and AIDS is disclosed.

Description

Technical field: [0001] The invention relates to the use of recombinant human lysozyme, in particular to the new use of recombinant human lysozyme in the preparation of medicines for treating wound infection and ulceration in the field of pharmacy. Background technique: [0002] Antibiotics have created many medical miracles and made many diseases disappear without a trace, such as pneumonia, meningitis, puerperal fever, sepsis, tuberculosis, etc. Today in the 21st century, the development of drug-resistant bacteria is shocking. For example, penicillin-resistant Streptococcus pneumoniae was very sensitive to penicillin, erythromycin, sulfonamide and other drugs in the past, but now it is almost "invulnerable". The resistance of Klebsiella pneumoniae to 16 kinds of high-end antibiotics such as Xilixin and Fudaxin is as high as 51.85%-100%. Staphylococcus aureus (MRSA) infection caused by burns, scalds, and poor peripheral microcirculation in the late stage of diabetes, woun...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/00A61K9/107A61K9/12A61K38/48A61P17/02
Inventor 张华
Owner 张华
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com